Latest Us Market Focus News

The Hydration Pharmaceuticals Company Limited (ASX: HPC) has had its trading suspension lifted as of 4 May 2026, following the lodgement of its delayed Annual Report revealing a $2.86 million net loss.

The Hydration Pharmaceuticals Company Limited (ASX: HPC) temporarily halted trading to relodge its FY25 Annual Report, revealing a $2.86 million loss driven by US market rationalisation and ongoing cost-cutting.

Orthocell has initiated commercial sales of its Remplir nerve repair device in Canada, leveraging a distributor-led model to penetrate a US$75 million market and setting the stage for broader North American expansion.

Neurizon Therapeutics has secured trademark protection for its NEURIZON® brand across major pharmaceutical markets, reinforcing its intellectual property strategy as it advances its lead drug candidate NUZ-001.

Genetic Signatures Limited unveiled a year of strategic transformation and robust financial growth at its 2025 AGM, highlighting leadership renewal and a sharpened commercial focus. The company’s FY25 revenue jumped 66%, driven by strong product demand and expanded market presence.

The Hydration Pharmaceuticals Company Limited reported a 55% reduction in half-year losses to $1.44 million, driven by strategic cost reductions and a sharpened focus on US e-commerce operations. Despite a 15% revenue decline, the company is banking on new product launches and retail expansion to fuel growth.

Wiseway Group has delivered its strongest financial performance since listing, powered by a booming US division and a sharp focus on eCommerce imports across key markets.

betr Entertainment Limited marked a transformative FY25 with a successful merger, strategic acquisitions, and a sharp reduction in losses, setting the stage for a major takeover bid of PointsBet.

Telix Pharmaceuticals has recast its historical financials from AUD to USD to better reflect its US-centric revenue streams and reports increased operating expenditure tied to recent acquisitions and growth initiatives.

AnteoTech has signed a binding Term Sheet with US-based Black Diamond Structures to jointly develop and commercialise an advanced battery additive combining their proprietary technologies, targeting improved lithium-ion battery anodes with higher silicon content.

BirdDog Technology reports a strategic pivot with four next-generation product launches, a 20% price increase, and a robust cash position, despite a 13% revenue decline in H1 FY25.